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The hypothalamus regulates the skeleton and adipose tissue via endocrine mechanisms. 
Changes in sex steroid levels in menopause and aging are central to the associated changes in 
bone mass and adiposity. Whereas many of these effects occur via direct actions on osteoblasts 
or adipocytes, sex hormones can also mediate effects on bone and adipose tissue via interaction 
with neuronal pathways. A key hypothalamic regulator of bone and adipose tissue is 
neuropeptide Y (NPY), which coordinately influences these tissues via effects on neuroendocrine 
and sympathetic nervous output. Better understanding of the interaction between NPY and sex 
steroids in regulating skeletal and energy homeostasis could lead to more effective treatments for 
osteoporosis and obesity. 
 
Neuroendocrine control of bone and fat 
Osteoporosis and excess central adiposity, increasingly prevalent in ageing populations, increase 
the risk of fractures and diseases such as type-2 diabetes mellitus, and adversely affect both 
quality of life and survival. The regulation of bone and adipose tissue mass has traditionally been 
studied independently, but osteoblasts and adipocytes are derived from the same mesenchymal 
precursor cells, and recent findings that the bone- or fat-derived hormones, osteocalcin and 
leptin, have significant effects on energy homeostasis and bone [1], respectively, now suggest 
that bone and adipose tissue share common regulatory pathways. The hypothalamus acts as a 
pivotal regulator of homeostasis in bone and adipose tissue via regulation of hypothalamo-
pituitary axes. For instance, activation of the hypothalamo-pituitary-adrenal axis, or inhibition of 
the hypothalamo-pituitary-somatotropic or -gonadotropic axes (as in stress or negative energy 
balance), can affect circulating concentrations of cortisol, insulin like growth factor-1 (IGF-1) and 
sex steroids that inhibit bone formation while promoting conservation of fat mass, particularly 
central adiposity 2, 3 and 4. Sex hormones – a major focus of this review – influence bone and fat 
via direct actions on osteoblasts or adipocytes 2, 3, 5, 6, 7 and 8. Recently, however, it has been 
recognized that sex hormones can influence these tissues via the neuropeptide Y (NPY) system 
(Box 1) 9, 10, 11 and 12, that also regulates bone and adipocyte homeostasis via actions in the 
hypothalamus and peripheral tissues 9, 13 and 14. In this review we examine the role of sex 
hormones in skeletal and energy homeostasis, with particular focus on their interaction with NPY. 
Whereas research into the isolated effects of sex hormones or the NPY system on bone and 
adipose tissue homeostasis has led to identification of potential novel drug targets for the 
treatment of osteoporosis or central obesity, emerging research into the interaction of these 
systems could pave the way for even better treatments for these conditions, particularly in the 
context of reduced circulating concentrations of sex hormones, as in menopause or ageing in 
women and in men. 
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Effects of sex hormones on bone and adipocyte homeostasis – direct actions 
Sex hormones are well known for their regulation of sexual development and reproductive 
functions 15 and 16. The most potent and dominant form of estrogen is 17β-estradiol. Estrogen 
mediates its actions by binding to the nuclear estrogen receptors alpha and beta (ERα and ERβ). 
ERα is primarily expressed in the uterus, liver, kidneys and heart, whereas ERβ is mainly 
expressed in the ovaries, the hematopoietic system and in the CNS [17]. Androgens are C-19 
steroids secreted mainly from the testes and adrenal glands. The main gonadal androgen in 
males is testosterone, bound in the circulation to albumin and sex hormone-binding globulin 
16 and 18. Testosterone can be irreversibly converted in peripheral tissues via the enzyme 5α-
reductase to the more potent 5α-dihydrotestosterone (DHT), and both DHT and testosterone can 
activate androgen receptor (AR) 16 and 18. Furthermore, testosterone can also be converted to 
17β-estradiol by an enzyme complex known as aromatase [16]. In addition to effects on 
reproductive organs and tissues, sex hormones play an essential role in bone metabolism. 
 The expression of both ERα and ERβ by bone cells opens the possibility of direct 
estrogen signaling in this tissue. Indeed, sex steroids such as estrogen indirectly regulate 
osteoclast action via signaling in the osteoblast [8], and sex hormone deficiency results in bone 
loss characterized by increased bone resorption [7]. Furthermore, the loss of estrogen following 
ovariectomy in rodents suppresses bone formation [19], whereas 17β-estradiol increases bone 
formation in vivo [20], and independently of changes in bone resorption [21]. Estrogen inhibits 
osteoclastogenesis by suppressing the production of the receptor activator of NF-κB ligand 
(RANKL), thereby increasing the production of the soluble decoy receptor osteoprotegerin (OPG) 
22 and 23, as well as via regulation of various bone-acting cytokines such as interleukins IL-1 and 
IL-6 and tumor necrosis factor (TNF) 24 and 25. Moreover, estrogen (as well as testosterone) 
inhibits bone resorption 26 and 27 by inducing osteoclast apoptosis [28] and suppressing activity 
of mature osteoclasts through direct receptor interactions [29]. In brief, estrogen has numerous 
effects on bone – some via direct tissue actions – to stimulate bone formation and decrease bone 
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In addition to estrogen effects on bone, androgens are
important regulators of bo e cell activity and bone mass in
both humans and mice [30]. ARs are found i both os eo-
blasts and osteoclasts; however, they are primarily
expressed in osteoblasts and to a greater degree in cortical
than cancellous bone [31]. The presence of AR in bone cells
suggests that androgens influence bone via direct tissue
effects. Indeed, selective deletion of AR in mature osteo-
blasts decreases bone mass [6] and reduces bone formation
[7], whereas chronic subcutaneous testosterone treatment
in rats stimulates bone formation [5,32]. These effects of
androgens on bonemass and bone formation are consistent
with the fact that low serum testosterone levels are a risk
factor for fracture in men, nearly doubling the risk of hip
fracture in men over 60 years of age [33]. Interestingly,
androgens also seem to be important regulators of bone
mass in women, because women with androgen-insensi-
tivity syndrome have lower bone mineral density despite
estrogen and progesterone treatment [34]. In summary,
androgens influence bone mass in men and likely also in
women, and this can occur via direct effects on bone cells,
particularly osteoblasts. This is in keeping with the finding
that failure of osteoblastic function in the early postme-
nopausal period in females, as well as in aging males, is
crucial for the development of osteoporosis [4,33].
In addition to effects on bone homeostasis, sex hormones
have pronounced effects on adipose tissue. Indeed, estro-
gen deficiency in female animals is associated with hyper-
phagia and increased body weight and adiposity,
particularly visceral adiposity [2,3,35,36]. In women, some
studies (although not all) report that menopause is associ-
ated with weight gain, even after controlling for the effects
of age [37,38]. Discrepancies among these studies are
probably due to the fact that body weight – often used in
large epidemiological studies – is not a reliable index of
body composition, and more accurate estimates of body
composition and fat distribution would lead to more con-
sistent findings. In fact, when central fat is specifically
measured, the majority of studies observe increased
abdominal or visceral adiposity at menopause [37,38]. In
both ovari ctomized animals and estrogen-deficient
women, administration of exogenous estrogens reduces
body weight gain, prevents abdominal or visceral fat gain
and educes loss of fat-free mass and muscle strength
[3,39,40], demonstrating the pivotal role of estrogens in
regulating body weight and body composition. ERa and
ERb rec ptors are present on adipocytes, and some of the
effec s of estrogens on fat mass take place via direct actions
on adipocytes to stimulate lipogenesis and lipid oxidation,
as recently reviewed [41], with regulation via genomic and
non-genomic regulation pathways [42], albeit other effects
f estrogen on fat mass are likely to be mediated within the
CNS (reviewed in Ref. [43]).
Epidemiological studies have demonstrated that serum
testosterone levels are inversely associated with whole
body and regional fat mass [44,45], suggesting a role for
androgens in adipose tissue metabolism. In men, the
observed gradual decline in circulating androgen levels
with aging is accompanied by increased total and abdomi-
nal fat [46]. Indeed, administration of aromatizable andro-
gen such as testosterone in older men reduces both total
and abdominal fat and increases lean mass [47–49],
whereas in vivo and in vitro studies show that androgens
play a significant role in altering fat accumulation and
distribution [50–53]. ARs are found in adipose tissue, with
more being present in visceral compared to subcutaneous
depots [54]. This is consistent with the greater influence of
androgen action in visceral adipose tissue. Via AR, andro-
gen exerts important functions on adipose tissue metab-
olism such as lipolysis and lipogenesis, preadipocyte
proliferation and adipogenesis (reviewed in Ref. [55]).
Box 1. The NPY system
The NPY system consists of three 36-amino acid peptides – NPY,
peptide YY (PYY) and pancreatic polypeptide (PP) – that act on at
least five G protein-coupled receptors (Y1, Y2, Y4, Y5 and y6) to
mediate numerous physiological functions [76,82,83]. NPY is a
neuromodulator predominantly expressed in the nervous system,
notably in the hypothalamus [84,85] and is co-localized with
catecholamines in sympathetic nerve terminals where it is thought
to regulate sympathetic output [86,87]. On the other hand, PYY and
PP are released into the circulation from gut tissues, notably L cells
in the colon [88] and F cells in the pancreatic islets of Langerhans
[89], respectively. Animal studies show that hypothalamic expres-
sion and secretion of NPY is markedly increased by energy
restriction, and this contributes to adaptive responses such as
increased appetite, reduced physical activity and reduced metabolic
rate that tend to promote weight regain [67]. Human evidence that
central NPY-ergic activity could be elevated in negative energy-
balance comes from the finding that anorexia nervosa is associated
with increased concentrations of NPY in cerebrospinal fluid [67]. The
obesogenic effects of NPY are thought to be largely mediated within
the hypothalamus, particularly via agonism of Y1 and Y5 receptors
[90]. By contrast, PYY and PP are released into the circulation in
response to food ingestion and are known to reduce food intake and
stimulate metabolic rate, predominantly via agonism of Y2 and Y4
receptors, respectively, in the brain stem and hypothalamus [91–97].
In addition to effects in the brain, the NPY system regulates energy
homeostasis via actions on Y1 and Y2 receptors in peripheral tissues
such as the liver and adipocytes [11,98]. Besides effects on energy
balance, the NPY system regulates numerous processes such as
fluid balance [99], immune function [100], circadian rhythms
[101,102], growth [103,104], reproduction [105,106] and skeletal
function.
Review Trends in Endocrinology and Metabolism Vol.21 No.7
412
Zenging	  et	  al.:	  Trends	  in	  Endocrinology	  &	  Metabolism,	  2(7):	  411-­‐418,	  2010	  
resorption. 
 In addition to estrogen effects on bone, androgens are important regulators of bone cell 
activity and bone mass in both humans and mice [30]. ARs are found in both osteoblasts and 
osteoclasts; however, they are primarily expressed in osteoblasts and to a greater degree in 
cortical than cancellous bone [31]. The presence of AR in bone cells suggests that androgens 
influence bone via direct tissue effects. Indeed, selective deletion of AR in mature osteoblasts 
decreases bone mass [6] and reduces bone formation [7], whereas chronic subcutaneous 
testosterone treatment in rats stimulates bone formation 5 and 32. These effects of androgens on 
bone mass and bone formation are consistent with the fact that low serum testosterone levels are 
a risk factor for fracture in men, nearly doubling the risk of hip fracture in men over 60 years of 
age [33]. Interestingly, androgens also seem to be important regulators of bone mass in women, 
because women with androgen-insensitivity syndrome have lower bone mineral density despite 
estrogen and progesterone treatment [34]. In summary, androgens influence bone mass in men 
and likely also in women, and this can occur via direct effects on bone cells, particularly 
osteoblasts. This is in keeping with the finding that failure of osteoblastic function in the early 
postmenopausal period in females, as well as in aging males, is crucial for the development of 
osteoporosis 4 and 33. 
 In addition to effects on bone homeostasis, sex hormones have pronounced effects on 
adipose tissue. Indeed, estrogen deficiency in female animals is associated with hyperphagia and 
increased body weight and adiposity, particularly visceral adiposity 2, 3, 35 and 36. In women, 
some studies (although not all) report that menopause is associated with weight gain, even after 
controlling for the effects of age 37 and 38. Discrepancies among these studies are probably due 
to the fact that body weight – often used in large epidemiological studies – is not a reliable index 
of body composition, and more accurate estimates of body composition and fat distribution would 
lead to more consistent findings. In fact, when central fat is specifically measured, the majority of 
studies observe increased abdominal or visceral adiposity at menopause 37 and 38. In both 
ovariectomized animals and estrogen-deficient women, administration of exogenous estrogens 
reduces body weight gain, prevents abdominal or visceral fat gain and reduces loss of fat-free 
mass and muscle strength 3, 39 and 40, demonstrating the pivotal role of estrogens in regulating 
body weight and body composition. ERα and ERβ receptors are present on adipocytes, and 
some of the effects of estrogens on fat mass take place via direct actions on adipocytes to 
stimulate lipogenesis and lipid oxidation, as recently reviewed [41], with regulation via genomic 
and non-genomic regulation pathways [42], albeit other effects of estrogen on fat mass are likely 
to be mediated within the CNS (reviewed in Ref. [43]). 
 Epidemiological studies have demonstrated that serum testosterone levels are inversely 
associated with whole body and regional fat mass 44 and 45, suggesting a role for androgens in 
adipose tissue metabolism. In men, the observed gradual decline in circulating androgen levels 
with aging is accompanied by increased total and abdominal fat [46]. Indeed, administration of 
aromatizable androgens such as testosterone in older men reduces both total and abdominal fat 
and increases lean mass 47, 48 and 49, whereas in vivo and in vitro studies show that androgens 
play a significant role in altering fat accumulation and distribution 50, 51, 52 and 53. ARs are 
found in adipose tissue, with more being present in visceral compared to subcutaneous depots 
[54]. This is consistent with the greater influence of androgen action in visceral adipose tissue. 
Via AR, androgen exerts important functions on adipose tissue metabolism such as lipolysis and 
lipogenesis, preadipocyte proliferation and adipogenesis (reviewed in Ref. [55]). Thus, reduction 
in androgen levels with ageing [37] could contribute to increased adiposity – particularly central 
adiposity [56] – that has been observed in older males, and this could be mediated at least in part 
via direct androgen signaling on adipocytes. 
 Taken together, these findings show that sex steroids represent an important regulatory 
influence in skeletal and adipose tissue. Local ER and AR expression on bone and adipose cells 
reinforces the crucial role of direct signaling in these tissues. Sex steroids, however, also interact 
with other regulatory systems such as the NPY system to mediate their effects on bone and 
adipose tissue. Before reviewing the recent data showing the interaction of sex hormones and 
NPY in the regulation of bone mass and adiposity, we will summarize the effects of the NPY 
system per se. 
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Hypothalamic actions of the NPY system in bone and adipose tissue 
Increasing evidence has linked efferent neural signaling from the hypothalamus to bone 
remodeling. Following initial studies on the central effects of leptin to reduce bone mass via 
activation of the sympathetic nervous system [57], a number of neuromodulatory molecules have 
been shown to influence the function of osteoblasts and osteoclasts 58 and 59. One of the most 
powerful centrally-mediated skeletal effects described to date involves the NPY system. Site-
specific overexpression of NPY in the hypothalamus of mice markedly reduced the capacity of 
osteoblasts to produce bone 60 and 61. The unilateral injection used in these studies excluded 
the potential for effects resulting from damage of the arcuate nucleus, as evident in studies using 
monosodium glutamate [62]. In mice overexpressing NPY in the hypothalamus, the rate of 
mineralized and unmineralized [61] bone formation was markedly (up to 7-fold) reduced on both 
the cortical and cancellous envelopes, resulting in a significant loss of bone mass. This loss of 
bone took place despite increasing body weight [61], a powerful stimulus for the accrual of bone 
mass [63]. 
 Consistent with the central inhibitory effect of NPY on osteoblast activity being mediated 
by Y2 receptors, conditional deletion of Y2 receptors from the hypothalamus of adult mice 
produced a generalized increase in osteoblast mineral apposition rate (MAR), with no evidence of 
changes in the bone resorption indices of osteoclast surface or osteoclast number [9]. 
Remarkably, MAR in cancellous bone of hypothalamus-specific Y2−/− mice was elevated 2-fold, in 
parallel with similar changes in cancellous bone volume [9]. In contrast to the central NPY 
overexpression model, that exhibited not only marked increases in body weight and adiposity but 
also hormonal changes (that could have contributed to the associated bone loss – e.g. increased 
serum leptin [57] and corticosterone [64] concentrations with concomitant reduction in serum IGF-
1 levels 57 and 65), central deletion of Y2 receptors did not produce any sustained changes in 
body weight or adiposity; serum leptin, IGF-1, T4 and calcium concentrations were also unaltered 
when measured in the non-fasted state [9]. Whereas serum corticosterone concentrations were 
elevated in these mice [9], this would be expected to reduce bone formation [64] rather than 
contribute to the observed increase in bone mass. These findings indicate that the bone anabolic 
phenotype observed in hypothalamic Y2-receptor-deficient mice could be mediated by non-
humoral factors, such as alterations in sympathetic nervous output to bone, an area of research 
in which studies are now underway. 
 A recent publication confirmed the inhibitory action of NPY on osteoblast activity, where 
NPY−/− mice showed an increase in cortical and cancellous bone mass in both axial and 
appendicular regions of the skeleton [61]. In cancellous bone, loss of NPY signaling induced an 
increase in osteoblastic MAR similar to that evident in hypothalamus-specific Y2−/− mice, with an 
additional increase in the surface extent of bone formation [61]. These osteoblast changes were 
associated with doubling of the rate at which cancellous bone is formed in these mice, with a 
concomitant increase in bone volume. In cortical bone, cross-section area and thickness were 
significantly greater in NPY−/− mice, and this effect was also due to increased bone formation [61]. 
Whereas these findings are in marked contrast to an initial assessment of vertebral cancellous 
bone in NPY−/− mice [57], further work by the same group showed significant increases in bone 
mass following loss of NPY-producing neurons from the arcuate neurons of the hypothalamus 
after monosodium glutamate treatment [62]. Thus, a number of lines of evidence now indicate 
that NPY acts within the hypothalamus to reduce bone mass, most likely via inhibition of 
osteoblast activity. 
 The positioning of NPY as a regulator of bone could offer a means by which the 
hypothalamus coordinately regulates bone mass and adiposity. It is particularly interesting that 
the relationship between hypothalamic NPY signaling and osteoblast activity is consistent with the 
relationship between body weight and bone mass. Hypothalamic NPY expression is highest 
during times of insufficient energy intake (Box 1). Elevated hypothalamic NPY expression, in 
addition to stimulating food intake and reducing physical activity and energy expenditure to 
protect against excessive body weight loss (Box 1), also inhibits bone formation [61]. This 
repression of osteoblast activity in energy deficit would have several benefits – conserving energy 
for essential processes and increasing the availability of minerals stored in bone, while not 
placing weight-bearing at risk because body weight is lower in periods of energy deficiency. In 
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contrast, during periods of energy excess in rodents, hypothalamic NPY expression is decreased, 
at least in the initial months [66], and this reduction of hypothalamic NPY expression could 
conceivably stimulate osteoblast activity, thereby increasing bone mass at a time when weight-
bearing due to increased adiposity is higher. In this manner, the NPY system is ideally placed to 
monitor body weight and modulate bone mass accordingly. This relationship has the potential to 
offer weight-bearing-like responses independent of actual bone loading, that is of potential clinical 
benefit for the maintenance of bone mass in patients on long-term bed rest. This dual regulation 
of bone mass and adiposity by NPY also has clinical implications in managing obesity. As lifestyle 
weight loss interventions in humans induce physiological changes that promote weight regain that 
could be mediated by increased hypothalamic NPY-ergic tonus (recently reviewed in Ref. [67]), it 
is conceivable that any such increase in central NPY expression could contribute to bone loss 
that might not necessarily be recovered by the time weight is regained, with possible detrimental 
effects for subsequent fracture risk. This interesting area of research requires further work to 
elucidate more clearly the bone response to weight loss. 
 
Local actions of the NPY system on osteoblasts and adipocytes 
Whereas NPY signaling in the hypothalamus regulates the activity of osteoblasts in the periphery, 
there appears to be other, non-central actions of the NPY system on bone formation. NPY−/− 
mice, in which NPY was specifically replaced only in the hypothalamus via virus-mediated 
transgene expression, showed only 50% normalization of the increased rate of mineral apposition 
(MAR) observed in germline knockout mice [61]. This partial effect highlights the potential for 
NPY actions in other areas in addition to its established function in the hypothalamus. Consistent 
with non-central effects of the NPY system on bone, the Y1 receptor has been identified as 
mediating peripheral actions of the NPY system on bone. Analysis of Y1−/− mice revealed an 
elevated bone-mass phenotype in association with a generalized increase in bone formation on 
both cancellous and cortical surfaces [14], similar to the phenotype of Y2−/− mice [9]. In contrast to 
the hypothalamus-specific action of Y2 receptors on bone, however, deletion of Y1 receptors from 
the hypothalamus had no effect on bone cell activity or bone volume, indicating that the effects of 
Y1 receptors on bone metabolism are mediated by non-hypothalamic receptors [14]. It is possible 
that Y1 receptors in regions of the brain other than the hypothalamus could be involved in 
mediating actions of NPY on bone; however, a direct effect of the NPY system on osteoblastic 
cells acting via locally-expressed Y1 receptors is more likely. Indeed, Y1 expression has been 
identified in mature osteoblasts and osteocytes, with expression levels increasing with greater 
differentiation [68]. This is supported by in situ hybridization that revealed Y1 receptor expression 
in osteoblasts on endocortical and cancellous surfaces within femoral bone tissue [69]. Moreover, 
these cells produce NPY and respond to mechanical load by reducing NPY expression [68], 
consistent with local regulatory action on osteoblastic activity. While hypothalamic NPY, acting 
through Y2 receptors, is ideally placed to modify bone mass in a generalized manner throughout 
the skeleton, NPY produced in bone itself and acting on Y1 receptors could play an important role 
in regulating bone mass, enabling local modulation of the generalized central signals. The load-
responsive nature of osteoblastic NPY expression is particularly appropriate for ensuring that a 
generalized bone anabolic affect is applied in an appropriate spatial manner for maximum weight-
bearing effect. This latter circuit offers an attractive target for pharmacological modulation and 
opens the possibility of increasing bone mass without affecting central NPY-ergic pathways. 
Investigation of mice with osteoblast-specific Y1 receptor deletion, currently under development in 
our laboratory, will be able to test these hypotheses. These effects of the NPY system on bone 
via Y1 and Y2 receptors are summarized in Figure 1. 
 Besides having direct actions influencing bone, the NPY system can exert direct effects 
on white adipose tissue. A high-fat diet combined with elevated glucocorticoid levels due to stress 
stimulates the production and release of NPY in peripheral sympathetic neurons as well as in 
adipose tissue [11]. This increased peptide level coincides with increased Y2 receptor expression 
in adipocytes, and blocking Y2 receptors specifically in adipocytes abrogates the increase in fat 
mass [11]. Therefore, while action of the satiety hormone peptide YY (PYY) on Y2 receptors in 
the brain would tend to reduce adiposity via reductions in food intake and metabolic rate (Box 1), 
agonism of Y2 receptors on adipocytes appears to have opposite effects, and instead promotes 
fat accumulation, at least under conditions of a high-fat diet and stress [11]. In light of the finding 
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that deletion of hypothalamic Y2 receptors increases bone mass, hypothalamic rather than 
peripheral Y2 receptors could be involved in matching an appropriate bone mass with body 
weight. Adipocytes also appear to undergo direct regulation via Y1 receptors that are expressed 
on adipocytes and preadipocytes. Here, Y1 receptors promote preadipocyte proliferation in 
response to NPY 70 and 71, mediate the anti-lipolytic effects of NPY, and inhibit lipolysis in 
rodent and human adipocytes in vitro 70 and 72. Therefore, agonism of Y1 receptors in the 
hypothalamus (Box 1) as well as in adipocytes [71], can induce changes that would promote fat 
accretion and weight gain, whereas Y1 receptor agonism would be expected to inhibit bone 
formation via direct effects on bone, judging from the high bone mass of Y1 receptor knockouts. 
As such, hypothalamic Y2 rather than Y1 receptors are more likely to be involved in the 
coordinated regulation of bone and fat mass. The role of Y1 and Y2 receptors in local regulation 
of adipocyte function is summarized in Figure 1. 
 
Actions of other members of the NPY system in the control of bone 
The complexity of the NPY system (Box 1) suggests the potential for multiple regulatory 
influences on bone. While pancreatic polypeptide (PP) appears to have no effect in bone, and 
mediated by increased hypothalamic NPY-ergic tonus
(recently reviewed in Ref. [67]), it is conceivable that
any such increase in central NPY expression could con-
tribute to bone loss that might not necessarily be recovered
by the time weight is regained, with possible detrimental
effects for subsequent fracture risk. This interesting area
of research requires further work to elucidate more clearly
the bone response to weight loss.
Local actions of the NPY system on osteoblasts and
adipocytes
WhereasNPY signaling in the hypothalamus regulates the
activity of osteoblasts in the periphery, there appears to be
other, non-central actions of the NPY system on bone
formation. NPY!/! mice, in which NPY was specifically
replaced only in the hypothalamus via virus-mediated
transgene expression, showed only 50% normalization of
the increased rate of mineral apposition (MAR) observed in
germline knockout mice [61]. This partial effect highlights
the potential for NPY actions in other areas in addition to
its established function in the hypothalamus. Consistent
with non-central effects of the NPY system on bone, the Y1
receptor has been identified as mediating peripheral
actions of the NPY system on bone. Analysis of Y1!/!mice
revealed an elevated bone-mass phenotype in association
with a generalized increase in bone formation on both
cancellous and cortical surfaces [14], similar to the pheno-
type of Y2!/! mice [9]. In contrast to the hypothalamus-
specific action of Y2 receptors on bone, however, deletion of
Y1 receptors from the hypothalamus had no effect on bone
cell activity or bone volume, indicating that the effects of
Y1 receptors on bone metabolism are mediated by non-
hypothalamic receptors [14]. It is possible that Y1 recep-
tors in regions of the brain other than the hypothalamus
could be involved in mediating actions of NPY on bone;
however, a direct effect of the NPY system on osteoblastic
cells acting via locally-expressed Y1 receptors is more
likely. Indeed, Y1 expression has been identified in mature
osteoblasts and osteocytes, with expression levels increas-
ing with greater differentiation [68]. This is supported by
in situ hybridization that revealed Y1 receptor expression
in osteoblasts on endocortical and cancellous surfaces
within femoral bone tissue [69]. Moreover, these cells
produce NPY and respond to mechanical load by reducing
NPY expression [68], consistent with local regulatory
action on osteoblastic activity. While hypothalamic NPY,
acting through Y2 receptors, is ideally placed to modify
bone mass in a generalized manner throughout the
skeleton, NPY produced in bone itself and acting on Y1
receptors could play an important role in regulating bone
mass, enabling local modulation of the generalized central
signals. The load-responsive nature of osteoblastic NPY
expression is particularly appropriate for ensuring that a
generalized bone anabolic affect is applied in an appro-
priate spatial manner for maximum weight-bearing effect.
This latter circuit offers an attractive target for pharma-
cological modulation and opens the possibility of increas-
ing bone mass without affecting central NPY-ergic
pathways. Investigation of mice with osteoblast-specific
Y1 receptor deletion, currently under development in
our laboratory, will be able to test these hypotheses. These
effects of the NPY system on bone via Y1 and Y2 r ceptors
ar summarized in Figure 1.
Besides having direct actions influencing bone, the NPY
system can exert direct effects on white adipose tissue. A
high-fat diet combined with elevated glucocorticoid levels
due to stress stimulates the production and release of NPY
in peripheral sympathetic neurons as well as in adipose
tissue [11]. This increased peptide level coincides with
increased Y2 receptor expression in adipocytes, and block-
ing Y2 receptors specifically in adipocytes abrogates the
increase in fat mass [11]. Therefore, while action of the
satiety hormone peptide YY (PYY) on Y2 receptors in the
brain would tend to reduce adiposity via reductions in food
intake and metabolic rate (Box 1), agonism of Y2 receptors
on adipocytes appears to have opposite effects, and instead
promotes fat accumulation, at least under conditions of a
high-fat diet and stress [11]. In light of the finding that
deletion of hypothalamic Y2 receptors increases bone
mass, hypothalamic rather than peripheral Y2 receptors
could be involved in matching an appropriate bone mass
with body weight. Adipocytes also appear to undergo direct
regulation via Y1 receptors that are expressed on adipo-
cytes and preadipocytes. Here, Y1 receptors promote pre-
adipocyte proliferation in response toNPY [70,71], mediate
Figure 1. Sex-steroid interactions with NPY in the regulation of bone and fat.
Negative energy balance, such as during starvation, enhances NPY expression in
the hypothalamus, that in turn inhibits osteoblast activity and bone formation
while promoting regain of lost fat mass. This process involves agonism of central
Y2 receptors and neuronal efferent signaling to the periphery. (a) In osteoblasts,
NPY released from sympathetic nerve terminals or potentially from osteoblasts
(that respond to mechanical loading with a decrease in NPY expression) also
signals via Y1 receptors to inhibit osteoblast activity. (b) In adipocytes, NPY from
sympathetic nerves or produced locally can signal via Y1 and Y2 receptors to
promote adipogenesis and fat accumulation. Sex steroids interact with this
pathway at multiple locations. Estrogen deficiency (green) stimulates
hypothalamic NPY production, thereby indirectly repressing osteoblast activity
and increasing adipocyte activity. Testosterone (red) appears to be required for the
stimulatory effect of Y1 deletion on osteoblast activity.
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PP-overexpressing transgenic mice have a similar bone mass to wild-type mice [73], reports 
concerning PYY are conflicting. In fact, PYY−/− mice have an osteopenic phenotype [74]. This 
finding is inconsistent with reports correlating elevated serum PYY levels with reduced bone 
mass in patients with anorexia nervosa [75]. Moreover, the osteopenic phenotype of PYY−/− mice 
is in contrast to the high bone mass of NPY−/− mice [60], despite PYY and NPY both able to signal 
through the same receptors [76]. Potentially, a mouse model that allows conditional 
overexpression of PYY in osteoblasts will shed light on the specific role of PYY in skeletal 
homeostasis. 
 To date, only Y1, Y2 and Y4 receptors have been studied with respect to effects on bone. 
In contrast to the situation with the Y1 and Y2 receptors, germline deletion of Y4 receptors did not 
induce changes in bone structure or cellular activity [73]. Furthermore, Y4 is predominantly 
activated by the ligand PP [77], that when overexpressed also had no skeletal effects [73]. 
However, Y4 receptors could play a modulatory role in bone in concert with Y2 receptors. Mice 
lacking both Y2 and Y4 receptors displayed a synergistic (3-fold) increase in cancellous bone 
volume and osteoblast activity compared to Y2−/− mice [73]. By contrast, cortical bone mass was 
significantly reduced in these animals compared to wild type. The increase in bone volume in 
Y2−/−Y4−/− mice was coincident with a decrease in adiposity and a marked decrease in serum 
leptin [73]. Leptin deficiency increases cancellous and decreases cortical bone mass via a 
mechanism separate to that involved in Y2−/− mice 9 and 57. The added increase in cancellous 
bone volume and decrease in cortical bone mass in Y2−/−Y4−/− mice could therefore represent the 
additive effects of deficiencies in both the leptin and Y2 pathways to bone, further reinforcing the 
separate nature of the two pathways and the complexity of neural inputs to the osteoblast. 
 Taken together, these findings demonstrate that NPY strongly regulates bone mass 
through both Y2 and Y1 receptor signaling, with deletion of Y2 receptors resulting in greater bone 
formation via effects in the hypothalamus, and deletion of Y1 receptors having a similar effect via 
non-hypothalamic pathways, most likely acting directly on bone cells (Figure 1). The powerful pro-
osteoblastic signals generated by inhibition of the NPY pathway to bone offer potential 
therapeutic application in common osteoporosis, such as post-menopause and with aging. While 
anti-resorptive agents are numerous, bone anabolic agents have proved difficult to generate, and 
only a single option is currently available [78]. The need for development of new anabolic 
treatments is clear. Moreover, the association of osteoporosis with reduced sex-steroid 
production warrants an understanding of how these pathways interact under hypogonadal 
conditions. 
 
Interactions between sex hormones and the NPY system in the control of bone and fat 
As outlined, the expression of ER and AR on bone cells and the characteristic in vitro changes 
subsequent to sex-steroid treatment have reinforced the role of direct action of these hormones 
on bone metabolism. However, indirect actions are also evident. Namely, a recent study 
demonstrated that estrogen signaling in the brain contributes to the regulation of the skeleton, 
with intracerebroventricular estrogen replacement in mice providing at least 1/3 of the total 
cancellous bone formation stimulated by estrogen supplementation [79]. Part of this regulation 
could conceivably take place via modulation of central NPY expression. Indeed, estrogen 
deficiency transiently increases hypothalamic NPY expression [80]; this could contribute to the 
bone loss (by suppressing osteoblast activity) and fat gain associated with estrogen deficiency 
because hypothalamic NPY overexpression reduces bone mass and increases adiposity 
60 and 65. Consistent with this mechanism, mean wall thickness, a direct measure of osteoblast 
activity, is reduced following ovariectomy [19]. Moreover, estrogen replacement after ovariectomy 
in rodents not only normalizes the elevated hypothalamic NPY expression, but also attenuates 
ovariectomy-induced bone loss and fat accumulation. These interactions between estrogen and 
NPY in the regulation of osteoblasts and adipocytes are shown in Figure 1. Further insight into 
the role of NPY in mediating bone loss and fat gain in response to sex steroid deficiency is 
currently under investigation in our laboratory, with investigation of gonadectomy in male and 
particularly female NPY−/− mice. 
 As shown above, lack of Y2 receptor signaling by members of the NPY family such as 
NPY results in elevated bone formation and bone mass [9]. Interestingly, while gonadectomy 
induces a significant reduction in cancellous bone volume in both wild-type and Y2−/− mice [13], 
Zenging	  et	  al.:	  Trends	  in	  Endocrinology	  &	  Metabolism,	  2(7):	  411-­‐418,	  2010	  	  
cancellous bone volume in gonadectomized Y2−/− mice remains significantly greater than that in 
wild-type mice [13]. Importantly, the elevated osteoblast activity that characterizes the skeletal 
phenotype of Y2−/− mice was maintained following gonadectomy in both female and male mice 
[13]. Moreover, protection against gonadectomy-induced bone loss was also evident following 
hypothalamus-specific deletion of Y2 receptors in both male and female mice [13]. This effect is 
attributable to improved bone formation, and is evident despite coincident increases in bone 
resorption [13]. Interestingly, the increase in fat mass that typically occurs after ovariectomy is 
prevented by germline deletion of Y2 receptors, and in male mice body weight and fat mass were 
consistently lower than wild type regardless of sex hormone status. This indicates a role for Y2 
receptors in the accumulation of adipose tissue in the hypogonadal state, and demonstrates that 
hypothalamic Y2 receptors constitutively restrain osteoblast activity even in the absence of sex 
hormones [13]. Thus, inhibition of hypothalamic NPY signaling via Y2 deletion provides relative 
protection against ovariectomy-induced bone loss and deterioration of bone microarchitecture in 
long bones, and inhibition of hypothalamic Y2 activity as a therapy for estrogen-deficient bone 
loss could thus be particularly effective. 
 Despite similarities in the cancellous and osteoblastic responses to Y1 and Y2 receptor 
deletion, important differences in the effects of sex-steroid deficiency are apparent in these 
models. In female Y1−/− mice, ovariectomy-induced osteopenia was reduced, attributable to the 
elevation in MAR, compared to that seen in wild-type mice [36]. Increased bone resorption 
resulting from sex steroid deficiency induces a subsequent increase in bone formation, albeit 
insufficient to prevent loss of bone. In wild-type and Y1−/− mice however, the relative increase in 
bone formation between sham-operated and ovariectomized mice is only half that evident in Y2−/− 
mice [36]. In male Y1−/− mice, a unique relationship was evident between NPY signaling and 
orchidectomy. The characteristic increase in MAR seen in these animals was abolished by 
androgen deficiency [36]. As a result, bones from orchidectomized Y1−/− mice were 
indistinguishable from similarly operated wild-type mice. This finding suggests that the bone 
anabolic responses mediated by Y1 deletion depends on intact androgen signaling (Figure 1). 
Thus, in the osteoblast, the presence of androgens is likely necessary for the anabolic activity of 
the Y1-deficient pathway. This study suggests that in addition to hypothalamic Y2 receptors 
modulating estrogen effects, osteoblastic Y1 receptors represent a novel site of interaction 
between classic endocrine and neural pathways in the regulation of bone homeostasis. Reduced 
androgen levels are a known risk factor for fracture in men [33] and are associated with reduced 
bone mass in women [81], and it could be that these relationships are in part the result of loss of 
Y1-mediated effects in bone, perhaps associated with loss of response to mechanical loading 
[68]. Moreover, any putative treatment regime aimed at attenuating Y1 activity to stimulate 
osteoblastic activity would benefit from sufficient endogenous androgens or low-dose adjunctive 
androgen treatment. 
 
Concluding remarks 
In summary, the hypothalamus has long been appreciated to be fundamental to the control and 
coordination of peripheral homeostatic activity. Historically, this has been viewed in terms of the 
extensive neuroendocrine system resulting from processing of hypothalamic signals relayed to 
the pituitary. Through these actions, endocrine signals are integrated throughout the body, 
modulating a vast array of physiological processes. Importantly, our understanding of the 
responses to these endocrine signals is crucial for the diagnosis and management of many 
disease processes. Sex steroids are a prime example of the power of endocrine signaling, with 
fundamental regulatory control over the production and maintenance of not only reproductive 
tissues, but also that of skeletal and adipose tissue. More recently, neural processes emanating 
from the hypothalamus are increasingly appreciated as powerful modulators of peripheral tissues. 
The NPY system is a clear example of this, exerting significant control over the functions of 
osteoblasts and adipocytes via effects in the hypothalamus and within bone and fat. Moreover, far 
from being distinct processes, neuroendocrine and neuronal pathways from the hypothalamus 
appear to act as a single coordinated regulatory system far more subtle and complex than when 
each is viewed in isolation. In this manner, hypothalamic regulation can now be viewed as a 
summation of both neuroendocrine and neural influences. As a result, our existing endocrine-
based understanding of diseases such as osteoporosis and obesity could be improved following 
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integration of neural inputs into the process. Nevertheless, our overall understanding of the NPY 
system remains incomplete; Box 2 presents a series of outstanding questions that will need to be 
answered before effective NPY-related therapeutics can be developed for these important human 
conditions. 
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In summary, the hypothalamus has long been appreciated
to be fundamental to the control and coordination of per-
ipheral homeostatic activity. Historically, this has been
viewed in terms of the extensive neuroendocrine system
resulting from processing of hypothalamic signals relayed
to the pituitary. Through these actions, endocrine signals
are integrated throughout the body, modulating a vast
array of physiological processes. Importantly, our under-
standing of the responses to these endocrine signals is
crucial for the diagnosis and management of many disease
processes. Sex steroids are a prime example of the power of
endocrine signaling, with fundamental regulatory control
over the production and maintenance of not only repro-
ductive tissues, but also that of skeletal and adipose tissue.
More recently, neural processes emanating from the hypo-
thalamus are increasingly appreciated as powerful modu-
lators of peripheral tissues. The NPY system is a clear
example of this, exerting significant control over the func-
tions of osteoblasts and adipocytes via effects in the hypo-
thalamus and within bone and fat. Moreover, far from
being distinct processes, neuroendocrine and neuronal
pathways from the hypothalamus appear to act as a single
coordinated regulatory system far more subtle and com-
plex than when each is viewed in isolation. In this manner,
hypothalamic regulation can now be viewed as a sum-
mation of both neuroendocrine and neural influences. As
a result, our existing endocrine-based understanding of
diseases such as osteoporosis and obesity could be
improved following integration of neural inputs into the
process. Nevertheless, our overall understanding of the
NPY system remains incomplete; Box 2 presents a series of
outstanding questions that will need to be answered before
effective NPY-related therapeutics can be developed for
these important human conditionsa¨.
Box 2. Outstanding Questions
General Questions
" What impact do these NPY-mediated pathways have on human
health and disease?
" Can understanding the interaction of endocrine and neural path-
ways improve diagnosis and/or treatment decisions in diseases
involving altered bone and fat metabolism?
" Do the pleiotropic actions of the NPY system preclude it as an
effective therapeutic agent? Can we specifically target peripheral
actions?
" What roles do other components of the NPY system (PYY, PP) play
in bone and fat metabolism?
NPY bone-related issues
" What are the functions and mechanisms of peripherally expressed
NPY in the osteoblast/adipocyte?
" What is the role of the sympathetic nervous system in mediating
the bone anabolic response following loss of hypothalamic Y2
receptor signaling?
NPY issues related to adipose-tissue
" Do alterations in NPY-mediated pathways play etiological roles in
human anorexia and obesity?
" Can NPY-mediated pathways be targeted as treatment to correct
body fat mass in human anorexia and obesity?
" Which Y receptor subtype(s) play major roles in mediating these
effects in adipose tissues and can therapeutic treatment target the
peripheral actions of NPY?
NPY and sex steroid-related issues
" Does increased action of the NPY system contribute to the bone
loss and fat gain observed following the menopause?
" Do sex hormones and NPY interact in determining whether a
mesenchymal stem cell will differentiate into a bone cell or an
adipocyte? If yes, at what level does this regulation occur? Can we
modify the interaction to control mesenchymal stem cell differ-
entiation and in turn increase bone mass at the expense of fat
mass?
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